Incannex and Mind Medicine Australia Launch Joint Venture to Open Psychedelic Therapies Clinic in Melbourne

Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combi...

June 18, 2025 | Wednesday | News
Medicovestor Receives FDA Orphan Drug Designation for Pancreatic Cancer ADC

Medicovestor, Inc., a biotechnology company advancing next-generation antibody-drug conjugates (ADCs), announced that the U.S. Food and Drug Administrati...

June 18, 2025 | Wednesday | News
Integrated DNA Technologies Expands Infectious Disease Portfolio With Advanced Solutions for Global Research and Surveillance

Integrated DNA Technologies (IDT), a global genomics leader, is expanding its infectious disease portfolio with new solutions to enhance worldwide research...

June 17, 2025 | Tuesday | News
Innovent Doses First Patient in Phase 3 Trial of Mazdutide for Obstructive Sleep Apnea and Obesity in China

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

June 16, 2025 | Monday | News
QIAGEN and Incyte Partner to Develop Global Companion Diagnostic Panel for CALR-Mutant Blood Cancers

QIAGEN N.V.  and Incyte  announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive portfolio...

June 16, 2025 | Monday | News
diaMentis Joins Dassault Systèmes’ 3DEXPERIENCE Lab to Advance FDA-Recognised Mental Health Diagnostic Technology

diaMentis, a company developing an innovative diagnostic support technology in mental health, recognized by the U.S. Food and Drug Administration (FDA) a...

June 13, 2025 | Friday | News
HepaRegeniX Doses First Patient in Phase Ib Trial of HRX-215 for Liver Regeneration After Colorectal Cancer Surgery

HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease, announced that...

June 11, 2025 | Wednesday | News
Metsera Reports Positive Phase 1 Results for MET-233i Showing Up to 8.4 Percent Weight Loss and Once-Monthly Dosing Potential

Metsera, Inc. announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leadin...

June 10, 2025 | Tuesday | News
OBI Pharma and TegMine Therapeutics Enter ADC Collaboration to Target Cancer-Specific Glycans

OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugate...

June 10, 2025 | Tuesday | News
Addex Therapeutics Reports Strong Preclinical Efficacy of GABAB Modulator for Chronic Cough

Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule all...

June 10, 2025 | Tuesday | News
Regeneron and Sanofi’s Dupixent Shows Strong Efficacy in Atopic Dermatitis Patients With Skin of Color

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall dise...

June 09, 2025 | Monday | News
Biocytogen and NJCTTQ Receive NMPA IND Approval for NTB003 to Treat Thyroid Eye Disease

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJC...

June 05, 2025 | Thursday | News
Trethera Secures Exclusive Worldwide License From UCLA to Expand TRE-515 Patent Protection

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune d...

June 04, 2025 | Wednesday | News
CERo Therapeutics Expands Global Patent Portfolio With New U.S. and European Grants Covering Lead Candidate CER-1236

CERo Therapeutics Holdings, Inc,an innovative immunotherapy company seeking to advance the next generation of  engineered T cell therapeutics that d...

June 03, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close